August 05, 2025 — Leads & Copy — Boundless Bio (Nasdaq: BOLD) reported its BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment. The company expects to submit an investigational new drug application for BBI-940 in the first half of 2026. It’s cash of $127 million supports operations into the first half of 2028.
“We are executing with sharpened focus on programs that we believe have the strongest scientific rationale and greatest potential to impact patients with oncogene-amplified cancers,” said Zachary Hornby, President and CEO of Boundless Bio.
Cash, cash equivalents, and short-term investments totaled $127.1 million as of June 30, 2025. Research and Development (R&D) expenses were $12.2 million for the second quarter of 2025, compared to $14.7 million for the same period in 2024. General and Administrative (G&A) expenses were $4.8 million for the second quarter of 2025, compared to $4.7 million for the same period in 2024. Net loss totaled $15.7 million for the second quarter of 2025, compared to $17.0 for the same period in 2024.
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors.
Investor Contacts:
James Lee, Boundless Bio, Inc.
jlee@boundlessbio.com
Renee Leck, THRUST Strategic Communications
renee@thrustsc.com
Media Contact:
Carly Scaduto
carly@carlyscadutoconsulting.com
